Global Antiemetic Drugs Market is segmented By Drug Type (5-HT3 receptor antagonists, Dopamine antagonists, Steroid-Corticosteroids, Benzodiazepines, NK1 receptor antagonist, Antihistamines, Cannabinoids, Anticholinergic), By Application (Chemotherapy, Pregnancy, Motion Sickness, Food Poisoning, Gastroenteritis, Diziness, General Anesthetics, Opiod Analgesics, Emotional Stress), By End-User (Hospital, Clinic, Nursing Home, Other), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Antiemetic Drugs Market Overview
The Global Antiemetic Drugs Market is expected to grow at a high CAGR during the forecast period (2024-2031).
The global antiemetic drugs market growth is driven by the fast-expanding of geriatric population worldwide that is highly susceptible to diseases such as cancer which is mostly treated through chemotherapy. North America region is dominating the global antiemetic drugs market accounted for the largest market share. Competitive rivalry intensifies with GlaxoSmithKline Pharmaceuticals Limited, Johnson & Johnson, Sanofi and others operating in the market.
Antiemetic drugs are those that can treat conditions such as nausea and vomiting. They can be used to treat the aforementioned conditions caused by a range of illnesses. Chemotherapy for cancer patients, food poisoning, gastroenteritis, motion sickness and so on can be treated by antiemetic drugs. In the case of pregnant women, these drugs bring significant relief to women who have to endure bouts of morning sickness, either during the early phase of the pregnancy.
Antiemetic Drugs Market Summary
|
Metrics |
Details |
|
Market CAGR |
High |
|
Segments Covered |
By Drug Type, By Application, By End-User, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other vital insights. |
|
Largest Market Share |
North America |
For More Insights Request Free Sample
Antiemetic Drugs Market Dynamics
The global antiemetic drugs market growth is driven by the fast-expanding of geriatric population worldwide that is highly susceptible to diseases such as cancer which is mostly treated through chemotherapy, something that results in side effects such as vomiting. In addition, a growing number of gastroenteritis patients are also serving to stoke demand.
Large companies manufacturing drugs are collaborating with the smaller company
Large companies manufacturing drugs, however, are partnering with smaller biotechnology and research companies to come up with newer and more effective antiemetic drugs. The small biotech research companies lack the necessary means to conduct various late-stage clinical trials that are usually capital intensive but often have strong research and development capabilities. Hence, large firms obtain the rights of the drug by paying the small companies one time. They also pay royalties on recurrent sales. Productivity in the antiemetic drugs market has also declined significantly in the past few years.
This has induced companies to rethink before undertaking any new molecule or drug research projects. Hence, large drug manufacturing companies have started collaborating with various small biotechnology and research companies. These small biotech research companies do not have sufficient capital to carry out various late-stage clinical trials that incur high capital expenditures but have strong R&D capabilities. Therefore, large firms obtain the rights of the drug through one-time payment to these small companies and some royalties are paid on recurrent sales. These factors are driving the growth of the market in the forecast period.
The increasing number of people being affected by different types of cancer
The increasing number of people being affected by different types of cancer is another factor driving the growth of the antiemetic drug market. Chemotherapy is one of the standard treatments used to deal with cancer and is also accompanied by side effects of nausea and vomiting. Chemotherapy accounts for the largest share of all the applications of the global antiemetic drugs market. These factors are driving the growth of the market in the forecast period.
The rising cost in various research and development processes is likely to hinder the antiemetic drugs market growth
However, the clinical pipeline for antiemetic drugs is dry and has been identified as one of the major factors likely to restrain the global antiemetic drugs market. Presently, rising cost in various research and development processes is exerting a lot of pressure on various drug-making companies. These factors are hampering the growth of the market in the forecast period.
COVID-19 Impact On Antiemetic Drugs Market
People with cancer face an elevated risk of infection and severe sequelae from COVID-19. Dexamethasone is commonly used for antiemetic prophylaxis with systemic therapy for cancer. However, dexamethasone is associated with an increased risk of viral and respiratory infections and causes lymphopenia, which is associated with worse outcomes during COVID-19 infections. Our purpose was to minimize dexamethasone exposure during antiemetic prophylaxis for systemic therapy for solid tumours during the COVID-19 pandemic while maintaining control of nausea and emesis.
Clinicians should prescribe the minimally effective dose of dexamethasone for antiemetic prophylaxis. Single-day dexamethasone dosing is recommended over multi-day dosing for regimens with high emetogenic risk excluding high-dose cisplatin, preferably in combination with palonosetron, netupitant, and olanzapine. For regimens with low emetogenic risk, 5-HT3 antagonists are recommended over dexamethasone. Thus the pandemic will drive the growth of the market in the forecast period
Antiemetic Drugs Market Segmentation Analysis
The dopamine antagonists segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
A dopamine antagonist is a chemical, medication or drug that prevents the actions stimulated by dopamine. Dopamine is a naturally produced chemical in the body that binds to regions in the brain to help regulate emotions and movement. Dopamine antagonists disrupt the activity of dopamine by blocking dopamine binding sites without activating them. These medications are used to treat a variety of disorders.
Most dopamine antagonists are used as medications for psychiatric disorders such as schizophrenia, psychosis and sometimes depression. Haloperidol (Haldol), chlorpromazine and risperidone (Risperdal) are classic dopamine antagonists used to treat the symptoms of psychosis -- a mental state in which a person loses touch with reality. Olanzapine (Zyprexa) is a newer dopamine antagonist commonly prescribed for schizophrenia. Dopamine antagonists can also be used for less common health problems, such as Tourette syndrome. Metoclopramide (Reglan) is a dopamine antagonist that is approved for use to treat some cases of severe acid reflux, or gastroesophageal reflux disease, and slow stomach emptying caused by diabetic nerve damage
The antiemetic drug in the dopamine antagonist category includes droperidol, metoclopramide, and domperidone. These medications are commonly used to treat nausea or vomiting. Side effects can include restlessness, muscle spasms, and drowsiness.
5-HT3 receptor antagonists have positive market growth in the forecast period. 5-HT3 receptor antagonists (also called serotonin receptor antagonists or serotonin blockers) are a class of medicines that are used for the prevention and treatment of nausea and vomiting, particularly those caused by chemotherapy, radiation therapy, or postoperatively. 5-HT3 is an abbreviation for serotonin that may also be written as 5-hydroxytryptamine. The first generation 5-HT3 receptor antagonists include dolasetron, granisetron, and ondansetron. Despite variations in their chemical structures and absorption rates, they all work in the same way and are well tolerated. The oral formulations are just as effective at preventing nausea and vomiting as the intravenous forms. These factors are driving the growth of the market in the forecast period.
The chemotherapy is expected to dominate the antiemetic drugs market during the forecast period
Chemotherapy is a drug treatment that uses powerful chemicals to kill fast-growing cells in the body. Chemotherapy is most often used to treat cancer since cancer cells grow and multiply much more quickly than most cells in the body. Many different chemotherapy drugs are available. Chemotherapy drugs can be used alone or in combination to treat a wide variety of cancers. Though chemotherapy is an effective way to treat many types of cancer, chemotherapy treatment also carries a risk of side effects. Some chemotherapy side effects are mild and treatable, while others can cause serious complications.
Chemotherapy often causes nausea and vomiting. A doctor may prescribe an antiemetic before and after chemo to help prevent these side effects and improve the quality of life. Different types of drugs can help, including serotonin and dopamine receptor blockers, NK1 receptor blockers, and corticosteroids. These factors are driving the market growth in the forecast period.
Antiemetic Drugs Market Geographical Share
North America region holds the largest market share global antiemetic drugs market
North America region is dominating the global antiemetic drugs market accounted for the largest market share in 2020, owing to well-established health care infrastructure, technological advancements, and favourable government support in the region. The rapid rise in the geriatric population and a growing number of cancer patients are boosting the market growth in the region. In addition, the highest rate owing to the rapid rise of health care infrastructure, rising disposable income of people, improving economic conditions, and increasing purchasing power of people will also drive the growth of the market.
Antiemetic Drugs Companies and Competitive Landscape
The antiemetic drugs market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include GlaxoSmithKline Pharmaceuticals Limited, Johnson & Johnson, Sanofi, Merck & Co., Novartis AG, Bristol-Myers Squibb, Astellas Pharma, Inc., Eli Lilly and Company, Abbott, Cipla Ltd., Dr. Reddy’s Laboratories Ltd, Baxter International, and IPCA Labs among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the antiemetic drugs market globally.
Sanofi S.A
Overview: Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Others.
Product Portfolio: The Company’s portfolio is comprised of drugs, generic medicines, food supplements, cosmetics, and medical devices such as cancer, cardiology, gynaecology, and diabetes.
